Steve Lincoln serves as General Counsel, Chief Compliance Officer for Semnur Pharmaceuticals. Prior to Semnur, Steve worked for Scilex Holding Company from 2019 to 2025.
Steve has been involved in the biopharma industry for more than 21 years.
Most recently, he was Counsel to the law firm of Brown Gee & Wenger, where his corporate practice included several publicly traded and private biopharma companies.
Before that, Steve served in in-house counsel roles at SciClone Pharmaceuticals (acquired by GL Capital), Kosan Biosciences (acquired by Bristol Myers Squibb), SuperGen (now Astex Pharmaceuticals, a subsidiary of Otsuka), and Protein Design Labs (later Facet Biotech, acquired by AbbVie).
Steve is a graduate of Brown University and the Boston University School of Law.
